doi.org/10.1016/s1470-2045(19)30827-7

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

..., Camilla Qvortrup
25
The Lancet Oncology35.90
Volume: 21, Issue: 3, Pages: 412 - 420
Published: Jan 27, 2020
Paper Fields
Paper Details
Title
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial
DOI
doi.org/10.1016/s1470-2045(19)30827-7
Published Date
Jan 27, 2020
Journal
The Lancet Oncology
Volume
21
Issue
3
Pages
412 - 420
© 2025 Pluto Labs All rights reserved.